Raymond James raised the firm’s price target on CymaBay to $33 from $17 and keeps a Strong Buy rating on the shares after the company announced topline results from its Phase 3 pivotal RESPONSE study to evaluate the safety and efficacy of seladelpar for the treatment of adult patients with primary biliary cholangitis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay (NASDAQ:CBAY) Rises on Promising Phase 3 Results in Liver Disease
- CymaBay RESPONSE data ‘positive all-around,’ says H.C. Wainwright
- CymaBay announces Phase 3 RESPONSE study achieved primary endpoint
- CymaBay to Host Investor Call to Share Topline Results from the Phase 3 RESPONSE Trial of Seladelpar in Primary Biliary Cholangitis on September 7, 2023
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)